702 related articles for article (PubMed ID: 36565708)
1. Same-day initiation of oral pre-exposure prophylaxis among gay, bisexual, and other cisgender men who have sex with men and transgender women in Brazil, Mexico, and Peru (ImPrEP): a prospective, single-arm, open-label, multicentre implementation study.
Veloso VG; Cáceres CF; Hoagland B; Moreira RI; Vega-Ramírez H; Konda KA; Leite IC; Bautista-Arredondo S; Vinícius de Lacerda M; Valdez Madruga J; Farias A; Lima JN; Zonta R; Lauria L; Tamayo CVO; Flores HJS; Santa Cruz YMC; Aguayo RMM; Cunha M; Moreira J; Makkeda AR; Díaz S; Guanira JV; Vermandere H; Benedetti M; Ingold HL; Pimenta MC; Torres TS; Grinsztejn B;
Lancet HIV; 2023 Feb; 10(2):e84-e96. PubMed ID: 36565708
[TBL] [Abstract][Full Text] [Related]
2. Factors associated with long-term HIV pre-exposure prophylaxis engagement and adherence among transgender women in Brazil, Mexico and Peru: results from the ImPrEP study.
Konda KA; Torres TS; Mariño G; Ramos A; Moreira RI; Leite IC; Cunha M; Jalil EM; Hoagland B; Guanira JV; Benedetti M; Pimenta C; Vermandere H; Bautista-Arredondo S; Vega-Ramirez H; Veloso VG; Caceres CF; Grinsztejn B;
J Int AIDS Soc; 2022 Oct; 25 Suppl 5(Suppl 5):e25974. PubMed ID: 36225148
[TBL] [Abstract][Full Text] [Related]
3. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
[TBL] [Abstract][Full Text] [Related]
4. Travestis, transgender women and young MSM are at high risk for PrEP early loss to follow-up in Rio de Janeiro, Brazil.
Echeverría-Guevara A; Coelho LE; Veloso VG; Pimenta MC; Hoagland B; Moreira RI; Leite I; Jalil EM; Cardoso SW; Torres TS; Grinsztejn B
Braz J Infect Dis; 2023; 27(1):102733. PubMed ID: 36586721
[TBL] [Abstract][Full Text] [Related]
5. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial.
Landovitz RJ; Hanscom BS; Clement ME; Tran HV; Kallas EG; Magnus M; Sued O; Sanchez J; Scott H; Eron JJ; Del Rio C; Fields SD; Marzinke MA; Eshleman SH; Donnell D; Spinelli MA; Kofron RM; Berman R; Piwowar-Manning EM; Richardson PA; Sullivan PA; Lucas JP; Anderson PL; Hendrix CW; Adeyeye A; Rooney JF; Rinehart AR; Cohen MS; McCauley M; Grinsztejn B;
Lancet HIV; 2023 Dec; 10(12):e767-e778. PubMed ID: 37952550
[TBL] [Abstract][Full Text] [Related]
7. High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project.
Hoagland B; Moreira RI; De Boni RB; Kallas EG; Madruga JV; Vasconcelos R; Goulart S; Torres TS; Marins LMS; Anderson PL; Luz PM; Costa Leite ID; Liu AY; Veloso VG; Grinsztejn B;
J Int AIDS Soc; 2017 Apr; 20(1):21472. PubMed ID: 28418232
[TBL] [Abstract][Full Text] [Related]
8. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study.
Molina JM; Ghosn J; Assoumou L; Delaugerre C; Algarte-Genin M; Pialoux G; Katlama C; Slama L; Liegeon G; Beniguel L; Ohayon M; Mouhim H; Goldwirt L; Spire B; Loze B; Surgers L; Pavie J; Lourenco J; Ben-Mechlia M; Le Mestre S; Rojas-Castro D; Costagliola D;
Lancet HIV; 2022 Aug; 9(8):e554-e562. PubMed ID: 35772417
[TBL] [Abstract][Full Text] [Related]
9. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Mayer KH; Molina JM; Thompson MA; Anderson PL; Mounzer KC; De Wet JJ; DeJesus E; Jessen H; Grant RM; Ruane PJ; Wong P; Ebrahimi R; Zhong L; Mathias A; Callebaut C; Collins SE; Das M; McCallister S; Brainard DM; Brinson C; Clarke A; Coll P; Post FA; Hare CB
Lancet; 2020 Jul; 396(10246):239-254. PubMed ID: 32711800
[TBL] [Abstract][Full Text] [Related]
10. Same-Day Initiation of Oral Pre-Exposure Prophylaxis is High Among Adolescent Men Who Have Sex With Men and Transgender Women in Brazil.
Soares F; Magno L; Pinto JA; Grangeiro A; Bruxvoort K; Greco D; Dourado I
J Adolesc Health; 2023 Dec; 73(6S):S26-S32. PubMed ID: 37953005
[TBL] [Abstract][Full Text] [Related]
11. Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study.
Grulich AE; Jin F; Bavinton BR; Yeung B; Hammoud MA; Amin J; Cabrera G; Clackett S; Ogilvie E; Vaccher S; Vickers T; McNulty A; Smith DJ; Dharan NJ; Selvey C; Power C; Price K; Zablotska I; Baker DA; Bloch M; Brown K; Carmody CJ; Carr A; Chanisheff D; Doong N; Finlayson R; Lewis DA; Lusk J; Martin S; Ooi C; Read P; Ryder N; Smith D; Tuck Meng Soo C; Templeton DJ; Vlahakis E; Guy R;
Lancet HIV; 2021 Aug; 8(8):e486-e494. PubMed ID: 34217426
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with self-reported adherence to daily oral pre-exposure prophylaxis among men who have sex with man and transgender women: PrEP Brasil study.
Monteiro Spindola Marins L; Silva Torres T; Luz PM; Moreira RI; Leite IC; Hoagland B; Kallas EG; Madruga JV; Grinsztejn B; Veloso VG;
Int J STD AIDS; 2021 Nov; 32(13):1231-1241. PubMed ID: 34311605
[TBL] [Abstract][Full Text] [Related]
13. Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study.
Gandhi M; Glidden DV; Mayer K; Schechter M; Buchbinder S; Grinsztejn B; Hosek S; Casapia M; Guanira J; Bekker LG; Louie A; Horng H; Benet LZ; Liu A; Grant RM
Lancet HIV; 2016 Nov; 3(11):e521-e528. PubMed ID: 27658870
[TBL] [Abstract][Full Text] [Related]
14. HPTN 083-02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study.
Psaros C; Goodman GR; Lee JS; Rice W; Kelley CF; Oyedele T; Coelho LE; Phanuphak N; Singh Y; Middelkoop K; Griffith S; McCauley M; Rooney J; Rinehart AR; Clark J; Go V; Sugarman J; Fields SD; Adeyeye A; Grinsztejn B; Landovitz RJ; Safren SA;
J Int AIDS Soc; 2024 May; 27(5):e26252. PubMed ID: 38783534
[TBL] [Abstract][Full Text] [Related]
15. HIV pre-exposure prophylaxis and its implementation in the PrEP Impact Trial in England: a pragmatic health technology assessment.
Sullivan AK; Saunders J; Desai M; Cartier A; Mitchell HD; Jaffer S; Ogaz D; Chiavenna C; Charlett A; Diamente V; Golombek R; Manavi K; Priestley C; Waters LJ; Milinkovic A; McOwan A; Estcourt C; Sabin CA; Rodger A; Gold D; Gazzard BG; McCormack S; Gill ON;
Lancet HIV; 2023 Dec; 10(12):e790-e806. PubMed ID: 38040478
[TBL] [Abstract][Full Text] [Related]
16. Adherence, Safety, and Feasibility of HIV Pre-Exposure Prophylaxis Among Adolescent Men Who Have Sex With Men and Transgender Women in Brazil (PrEP1519 Study).
Dourado I; Soares F; Magno L; Amorim L; Eustorgio Filho M; Leite B; Greco D; Westin M; Tupinambás U; Massa P; Miura Zucchi E; Grangeiro A
J Adolesc Health; 2023 Dec; 73(6S):S33-S42. PubMed ID: 37953006
[TBL] [Abstract][Full Text] [Related]
17. Barriers and facilitators to pre-exposure prophylaxis uptake among male sex workers in Mexico: an application of the RE-AIM framework.
Kadiamada-Ibarra H; Hawley NL; Sosa-Rubí SG; Wilson-Barthes M; Franco RR; Galárraga O
BMC Public Health; 2021 Nov; 21(1):2174. PubMed ID: 34837988
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial.
Marzinke MA; Hanscom B; Wang Z; Safren SA; Psaros C; Donnell D; Richardson PA; Sullivan P; Eshleman SH; Jennings A; Feliciano KG; Jalil E; Coutinho C; Cardozo N; Maia B; Khan T; Singh Y; Middelkoop K; Franks J; Valencia J; Sanchez N; Lucas J; Rooney JF; Rinehart AR; Ford S; Adeyeye A; Cohen MS; McCauley M; Landovitz RJ; Grinsztejn B;
Lancet HIV; 2023 Nov; 10(11):e703-e712. PubMed ID: 37783219
[TBL] [Abstract][Full Text] [Related]
19. Factors Associated With Willingness to Use Pre-Exposure Prophylaxis in Brazil, Mexico, and Peru: Web-Based Survey Among Men Who Have Sex With Men.
Torres TS; Konda KA; Vega-Ramirez EH; Elorreaga OA; Diaz-Sosa D; Hoagland B; Diaz S; Pimenta C; Bennedeti M; Lopez-Gatell H; Robles-Garcia R; Grinsztejn B; Caceres C; Veloso VG;
JMIR Public Health Surveill; 2019 Jun; 5(2):e13771. PubMed ID: 31210143
[TBL] [Abstract][Full Text] [Related]
20. Youth-friendly services and a mobile phone application to promote adherence to pre-exposure prophylaxis among adolescent men who have sex with men and transgender women at-risk for HIV in Thailand: a randomized control trial.
Songtaweesin WN; Kawichai S; Phanuphak N; Cressey TR; Wongharn P; Saisaengjan C; Chinbunchorn T; Janyam S; Linjongrat D; Puthanakit T;
J Int AIDS Soc; 2020 Sep; 23 Suppl 5(Suppl 5):e25564. PubMed ID: 32869511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
